¼¼°èÀÇ Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀå º¸°í¼­(2025³â)
Tumor Profiling Global Market Report 2025
»óǰÄÚµå : 1760734
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,192,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,951,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,709,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â¿¡´Â 10.1%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 164¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¿¹»óµÇ´Â ¼ºÀåÀº ¾×ü»ý°Ë ±â¼ú äÅà Áõ°¡, ¾Ï ¿¬±¸ °³¹ß ÅõÀÚ Áõ°¡, °í·ÉÈ­, Ç¥ÀûÄ¡·áÁ¦ »ç¿ë È®´ë, ¾Ï ¿¬±¸ Çù·Â Áõ°¡ µîÀÇ ¿äÀο¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ±â°£À» Çü¼ºÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â µ¿¹ÝÁø´ÜÀ¸·ÎÀÇ Àüȯ, ´ÙÁß À¯ÀüÀÚ °Ë»ç Áõ°¡, Â÷¼¼´ë ½ÃÄö½Ì ±â¼ú Çõ½Å, ¾Ï Áø´Ü¿¡ ÀΰøÁö´É(AI)ÀÇ ÅëÇÕ, Á¾¾ç ÇÁ·ÎÆÄÀϸµ ±â¼úÀÇ ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù.

¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ÇâÈÄ ¸î ³â µ¿¾È Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸ÂÃãÀÇ·á´Â ȯÀÚ °³°³ÀÎÀÇ Æ¯¼º¿¡ ¸Â°Ô ÀÇ·á Ä¡·á¸¦ Á¶Á¤ÇÏ´Â °ÍÀ¸·Î, ±âÁ¸ Ä¡·á¿Í ºñ±³ÇÏ¿© ´õ ³ªÀº °á°ú¿Í ºÎÀÛ¿ëÀÌ Àû°í ´õ Á¤È®ÇÑ Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. Á¾¾ç ÇÁ·ÎÆÄÀϸµÀº ȯÀÚÀÇ Á¾¾ç¿¡¼­ ƯÁ¤ À¯ÀüÀÚ º¯ÀÌ ¹× ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°ÇÏ¿© ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϴ ǥÀû Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ¸ÂÃãÀÇ·á¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 2¿ù, ¹Ì±¹¿¡ ±â¹ÝÀ» µÐ °³ÀθÂÃãÀÇ·á ÃßÁø ´ÜüÀÎ °³ÀθÂÃãÀǷῬÇÕ(Personalized Medicine Coalition)Àº 2023³â ½Å¾à ½ÂÀÎ °Ç¼ö¿¡¼­ °³ÀθÂÃãÀÇ·á°¡ Â÷ÁöÇÏ´Â ºñÀ²ÀÌ 1/3À» ³Ñ¾î¼¹À¸¸ç, ÀÌ·¯ÇÑ Ãß¼¼´Â 4³â ¿¬¼ÓÀ¸·Î Áö¼ÓµÉ °ÍÀ̶ó°í º¸°íÇß½À´Ï´Ù. ±× °á°ú, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº ¾Ï Ä¡·áÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» Çâ»ó½Ã۱â À§ÇØ ÀΰøÁö´É(AI) ±â¹Ý Áø´Ü µµ±¸¸¦ Æ÷ÇÔÇÑ Ã·´Ü ¼Ö·ç¼Ç °³¹ß¿¡ Á¡Á¡ ´õ ÁýÁßÇϰí ÀÖÀ¸¸ç, AI´Â º¹ÀâÇÑ À¯Àüü, ÇÁ·ÎÅ×¿È ¹× ÀÓ»ó µ¥ÀÌÅ͸¦ ºÐ¼®Çϱâ À§ÇÑ °í±Þ ÄÄÇ»ÆÃ ±â¼úÀ» Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù. º¸´Ù ºü¸¥ Áø´Ü, °³ÀÎÈ­µÈ Ä¡·á °èȹ, ´õ ³ªÀº º´»ó ÁøÇà ¸ð´ÏÅ͸µÀÌ ¿ëÀÌÇØÁý´Ï´Ù. ¿¹¸¦ µé¾î, 2025³â 1¿ù ¾Ï Áø´Ü ¹× Ä¡·á¸¦ À§ÇÑ AI ±â¹Ý ¼ÒÇÁÆ®¿þ¾î Àü¹® ±â¾÷ÀÎ ¿µ±¹ÀÇ Panakeia Technologies LTD´Â PANProfiler ColonÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ AI ±â¹Ý ¼ÒÇÁÆ®¿þ¾î´Â ´ëÀå¾Ï Á¶Á÷ »ùÇÃÀÇ H ¹× E ¿°»ö À̹ÌÁö¸¦ »ç¿ëÇÏ¿© ¸¶ÀÌÅ©·Î À§¼º ºÒ¾ÈÁ¤¼º(MSI) ¹× ºÒÀÏÄ¡ º¹±¸ °á¼Õ(dMMR)°ú °°Àº ÁÖ¿ä ºÐÀÚ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ÇÁ·ÎÆÄÀϸµÇϵµ·Ï Ưº°È÷ °í¾ÈµÇ¾ú½À´Ï´Ù. ÀÌ µµ±¸´Â Á¾¾çÀÇ ½Å¼ÓÇϰí Á¤È®ÇÑ ºÐÀÚ ÇÁ·ÎÆÄÀϸµÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ´ëÀå¾Ï Áø´Ü, ¸°Ä¡ ÁõÈıº ½Äº° ¹× ¸ÂÃã Ä¡·á °áÁ¤¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í ÄڷγªÀç³­°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Tumor profiling is a collection of methods used to examine and characterize the genetic and molecular characteristics of a tumor. This process helps identify specific mutations, gene expression patterns, and other molecular traits of cancer cells, providing valuable insights into the biology of the tumor. It also aids in treatment decision-making and supports the development of personalized therapies.

The primary techniques used in tumor profiling include genomics, proteomics, epigenetics, and metabolomics. Genomics involves studying the genetic material (DNA) of cancer cells to identify genetic alterations that drive tumor formation and progression. It uses technologies such as sequencing, quantitative polymerase chain reaction (qPCR), immunohistochemistry, in situ hybridization (ISH), and microarrays. These techniques are commonly applied in personalized cancer treatment, oncological diagnostics, and research.

The tumor profiling market research report is one of a series of new reports from The Business Research Company that provides tumor profiling market statistics, including tumor profiling industry global market size, regional shares, competitors with a tumor profiling market share, detailed tumor profiling market segments, market trends and opportunities, and any further data you may need to thrive in the tumor profiling industry. This tumor profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tumor profiling market size has grown rapidly in recent years. It will grow from $10.16 billion in 2024 to $11.21 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth observed in the historic period can be attributed to several factors, including the rising prevalence of cancer cases, growing demand for personalized medicine, increased healthcare spending, wider adoption of companion diagnostics, and heightened awareness of the importance of early cancer detection.

The tumor profiling market size is expected to see rapid growth in the next few years. It will grow to $16.48 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth anticipated during the forecast period can be attributed to factors such as the increasing adoption of liquid biopsy techniques, rising investments in cancer research and development, an aging population, the expanding use of targeted therapies, and a growing number of cancer research collaborations. Key trends expected to shape this period include a shift toward companion diagnostics, an increase in multi-gene testing, technological innovations in next-generation sequencing, the integration of artificial intelligence (AI) in cancer diagnostics, and advancements in tumor profiling technologies.

The growing demand for personalized medicine is expected to fuel the growth of the tumor profiling market in the coming years. Personalized medicine tailors healthcare treatments to the unique characteristics of each patient, offering more precise therapies with better outcomes and fewer side effects compared to traditional treatments. Tumor profiling plays a key role in personalized medicine by identifying specific genetic mutations and biomarkers in a patient's tumor, enabling targeted therapies that minimize side effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization focused on advancing personalized medicine, reported that personalized medicines accounted for over one-third of all new drug approvals in 2023, marking the fourth consecutive year of this trend. As a result, the rising demand for personalized medicine is driving the expansion of the tumor profiling market.

Leading companies in the tumor profiling market are increasingly focusing on developing advanced solutions, including artificial intelligence (AI)-powered diagnostic tools, to improve the accuracy and efficiency of cancer treatment. AI involves the use of advanced computational techniques to analyze complex genomic, proteomic, and clinical data, facilitating faster diagnoses, personalized treatment plans, and better disease progression monitoring. For example, in January 2025, Panakeia Technologies LTD, a UK-based company specializing in AI-driven software for cancer diagnosis and treatment, introduced PANProfiler Colon. This AI-powered software is specifically designed to profile key molecular biomarkers, such as microsatellite instability (MSI) and mismatch repair deficiency (dMMR), using H and E-stained images of colon cancer tissue samples. The tool allows for rapid and precise molecular profiling of tumors, which is crucial for diagnosing colorectal cancer, identifying Lynch syndrome, and guiding personalized treatment decisions.

In February 2024, Myriad Genetics Inc., a U.S.-based leader in genetic testing and precision medicine, acquired assets from Intermountain Precision Genomics (IPG) for an undisclosed amount. This acquisition bolsters Myriad's precision oncology portfolio by incorporating IPG's precise tumor test, precise liquid test, and its CLIA-certified laboratory in St. George, Utah, all aimed at advancing patient care. Intermountain Precision Genomics is a US-based division specializing in molecular diagnostics, genomic testing, and tumor profiling.

Major players in the tumor profiling market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Guardant Health Inc., GenScript Biotech Corporation, NeoGenomics Inc., Caris Life Sciences Inc., Tempus Inc., Foundation Medicine Inc., NanoString Technologies Inc., Personalis Inc., Boreal Genomics Inc., Strand Life Sciences Pvt. Ltd., HTG Molecular Diagnostics Inc., Lucence Health Inc., and Predictive Oncology Inc.

North America was the largest region in the tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tumor profiling report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tumor profiling market includes revenues earned by entities by providing services such as biomarker testing, methylation profiling, and clinical trial matching. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor profiling market also includes sales of liquid biopsy kits, immunohistochemistry (IHC) kits, and methylation profiling kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tumor Profiling Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tumor profiling market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for tumor profiling ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tumor profiling market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Tumor Profiling Market Characteristics

3. Tumor Profiling Market Trends And Strategies

4. Tumor Profiling Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Tumor Profiling Growth Analysis And Strategic Analysis Framework

6. Tumor Profiling Market Segmentation

7. Tumor Profiling Market Regional And Country Analysis

8. Asia-Pacific Tumor Profiling Market

9. China Tumor Profiling Market

10. India Tumor Profiling Market

11. Japan Tumor Profiling Market

12. Australia Tumor Profiling Market

13. Indonesia Tumor Profiling Market

14. South Korea Tumor Profiling Market

15. Western Europe Tumor Profiling Market

16. UK Tumor Profiling Market

17. Germany Tumor Profiling Market

18. France Tumor Profiling Market

19. Italy Tumor Profiling Market

20. Spain Tumor Profiling Market

21. Eastern Europe Tumor Profiling Market

22. Russia Tumor Profiling Market

23. North America Tumor Profiling Market

24. USA Tumor Profiling Market

25. Canada Tumor Profiling Market

26. South America Tumor Profiling Market

27. Brazil Tumor Profiling Market

28. Middle East Tumor Profiling Market

29. Africa Tumor Profiling Market

30. Tumor Profiling Market Competitive Landscape And Company Profiles

31. Tumor Profiling Market Other Major And Innovative Companies

32. Global Tumor Profiling Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tumor Profiling Market

34. Recent Developments In The Tumor Profiling Market

35. Tumor Profiling Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â